TheraRadar
← Back
Data updated: Mar 29, 2026

UPJOHN

NeurologyCardiovascularMetabolic
Big Pharma

UPJOHN is a major pharmaceutical company focused on Neurology, Cardiovascular, Metabolic. Key products include LYRICA CR.

1981
Since
12
Drugs
-
Trials
6
Approved (2yr)

Key Drugs

LYRICA CR
pregabalin
Pain
alpha 2 ‑delta subunit of voltage‑gated calcium channels 3 indications · 2017

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

INSPRA 2025-06-16
Labeling
LYRICA 2025-04-25
Labeling
LYRICA 2025-04-25
Labeling
LYRICA CR 2025-04-25
Labeling
CELEBREX 2024-11-21
Labeling
LIPITOR 2024-04-02
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Neurology 38%
3 drugs
Cardiovascular 25%
2 drugs
Metabolic 13%
1 drugs
Immunology 13%
1 drugs
Ophthalmology 13%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Novartis big-pharma
Cardiovascular, Immunology, Ophthalmology
Merck big-pharma
Cardiovascular, Immunology, Metabolic
AbbVie big-pharma
Immunology, Neurology, Ophthalmology
Johnson & Johnson big-pharma
Immunology, Cardiovascular, Metabolic
Eli Lilly big-pharma
Metabolic, Immunology, Neurology